^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TCF3-PBX1 fusion

i
Other names: PBX1, PBX Homeobox 1, Pre-B-Cell Leukemia Transcription Factor 1, Pre-B-Cell Leukemia Homeobox 1, Homeobox Protein PBX1, Homeobox Protein PRL, TCF3, Transcription Factor 3, Immunoglobulin Transcription Factor 1, Transcription Factor E2-Alpha 2, Kappa-E2-Binding Factor 2, BHLHb21, ITF1, E2A, Class B Basic Helix-Loop-Helix Protein 21, Transcription Factor ITF-1, VDR Interacting Repressor, TCF-3, VDIR, E47, P75, Transcription Factor 3 (E2A Immunoglobulin Enhancer Binding Factors E12/E47), Negative
Entrez ID:
Related biomarkers:
6ms
Transcription factor abnormalities in B-ALL leukemogenesis and treatment. (PubMed, Trends Cancer)
In addition, the therapeutic options and prognoses for patients who harbor these TF abnormalities are discussed. This review aims to provide an up-to-date panoramic view of how TF-based oncogenic fusions might drive carcinogenesis and impact on potential therapeutic exploration of B-ALL treatments.
Review • Journal
|
RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1) • MEF2D (Myocyte Enhancer Factor 2D) • DUX4 (Double Homeobox 4) • ZNF384 (Zinc Finger Protein 384)
|
TCF3-PBX1 fusion
over1year
Journal • FDG PET
|
TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
|
TCF3-PBX1 fusion
2years
Incidence and Prognostic Impact of TCF3-PBX1 Fusion in Childhood Acute Lymphoblastic Leukemia: A Single Centre Experience. (PubMed, Indian J Hematol Blood Transfus)
Day -8 prednisolone response and morphological remission at the end of induction was similar in both study groups. 5-year overall and event free survival for those with and without fusion was 75%, 70.1% and 79.5%, 69.5% respectively.The incidence of TCF3-PBX1 fusion in the present study was 4.4% and it does not have an independent prognostic significance.
Journal
|
TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
|
TCF3-PBX1 fusion
over2years
Detection of PAX5 Overexpression By RNA-Seq for B-Cell Lineage Detection in Acute Lymphocytic Leukemia (ASH 2021)
In this study we demonstrate that NeoGenomics's (heme) NGS assay can be used for PAX5 gene over-expression analysis on ALL. The heme NGS is inexpensive and is already integrated in the benchwork workflow without adding extra burden and can be used as an objective quantification of PAX5 levels overcoming the challenges associated with the relative signal intensity biases in IHC testing. This type of RNA testing can be useful especially with specimens having limited material.
Preclinical
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PAX5 (Paired Box 5) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1) • RPL5 (Ribosomal Protein L5)
|
TCF3-PBX1 fusion • PAX5 overexpression
over2years
Characterization of the immunophenotypic aberrancies with respect to common fusion transcripts in B-cell precursor acute lymphoblastic leukaemia - a report of 986 Indian patients. (PubMed, Turk J Haematol)
Aberrant myeloid CD markers can be used in predicting chimeric fusion transcripts at baseline, so as to plan desirable TKI therapy in BCP-ALL cases with specific chimeric fusion transcripts. This study delineates the relationship of chimeric fusion transcripts with the aberrant expression of myeloid markers in a large cohort of BCP-ALL cases.
Clinical • Journal
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • CD33 (CD33 Molecule) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
|
BCR-ABL1 fusion • TCF3-PBX1 fusion
over2years
Cryptic TCF3 fusions in childhood leukemia - detection by RNA-sequencing. (PubMed, Genes Chromosomes Cancer)
For the TCF3 fusions we obtained discrepant results with the different methods, which are described in the article. Taken together, translocations leading to TCF3 fusion genes might appear cryptic and may remain undetected by a single method.
Clinical • Journal
|
TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
|
TCF3-PBX1 fusion
almost3years
Clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China. (PubMed, Curr Probl Cancer)
In contrast to previous studies, childhood ALL patients with TCF3-PBX1 transcripts do not appear to show a better outcome than their negative counterparts. TCF3/PBX1 positive was a definitive intermediate risk factor with our NPCLC-ALL-2008 protocol.
Retrospective data • Journal
|
TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
|
TCF3-PBX1 fusion
|
prednisone
almost3years
[VIRTUAL] THE PROGNOSTIC SIGNIFICANCE OF ZNF384 FUSIONS IN ADULT PH-NEGATIVE B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (EHA 2021)
In addition, ZNF384 fusion was not an independent prognostic factor for both RFS and OS in both adult Ph-negative BCP-ALL and B-other patients. Conclusion ZNF384 fusion is common in adult BCP-ALL, which may define a new group from BCP-ALL containing no classical fusion transcript with better prognosis through receiving allo-HSCT.
Clinical
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • CREBBP (CREB binding protein) • EWSR1 (EWS RNA Binding Protein 1) • EP300 (E1A binding protein p300) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1) • TAF15 (TATA-Box Binding Protein Associated Factor 15)
|
MLL rearrangement • MLL rearrangement • TCF3-PBX1 fusion
almost3years
[VIRTUAL] T(1;19)(Q23;P13) TCF3-PBX1 MAY NOT BE AN INTERMEDIATE-RISK SUBTYPE IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH MRD-ORIENTED PROTOCOLS FROM THE PETHEMA GROUP (EHA 2021)
Conclusion Although showing favorable initial treatment response, pts with t(1;19) experience a higher rate of relapse (especially those with ACA to t(1;19)) than the remaining BCP ALL pts, without differences in OS. A deeper genetic analysis may identify markers of poor outcome enabling a more precise risk stratification of t(1;19) pts.
Clinical
|
TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
|
TCF3-PBX1 fusion
3years
Co-occurrence of TCF3-PBX1 gene fusion, and chromosomal aberration in a pediatric pre-B cell acute lymphoblastic leukemia with clitoris swelling: A case report and literature review. (PubMed, Medicine (Baltimore))
The clinical symptoms of ALL with clitoris swelling are not typical, with a high rate of misdiagnosis. When the cause of clitoris swelling is unknown, ALL should be considered. Bone marrow aspiration must be done before doing a more invasive investigation like biopsy.
Clinical • Review • Journal
|
TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
|
TCF3-PBX1 fusion